Vericel (NASDAQ:VCEL) Trading Down 4.8% - Time to Sell?

Vericel Corporation (NASDAQ:VCEL - Get Free Report) traded down 4.8% during mid-day trading on Tuesday . The stock traded as low as $38.08 and last traded at $37.90. 46,138 shares were traded during trading, a decline of 89% from the average session volume of 420,806 shares. The stock had previously closed at $39.82.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Stephens reiterated an "overweight" rating and set a $67.00 price objective on shares of Vericel in a research report on Monday, June 16th. Truist Financial reduced their price objective on Vericel from $61.00 to $51.00 and set a "buy" rating for the company in a research report on Friday, April 11th. Finally, Wall Street Zen downgraded Vericel from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.14.

Vericel Stock Performance

The business has a 50 day simple moving average of $41.85 and a 200-day simple moving average of $47.23. The stock has a market capitalization of $1.87 billion, a P/E ratio of 1,237.75 and a beta of 1.32.

Vericel (NASDAQ:VCEL - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.14). The firm had revenue of $52.60 million for the quarter, compared to the consensus estimate of $53.86 million. Vericel had a net margin of 1.25% and a return on equity of 1.09%. The business's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.08) earnings per share. Equities research analysts forecast that Vericel Corporation will post 0.14 EPS for the current fiscal year.

Institutional Investors Weigh In On Vericel

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. lifted its position in shares of Vericel by 1.6% during the 1st quarter. Invesco Ltd. now owns 2,273,494 shares of the biotechnology company's stock valued at $101,443,000 after acquiring an additional 35,345 shares during the last quarter. Congress Asset Management Co. lifted its position in shares of Vericel by 18.0% during the 2nd quarter. Congress Asset Management Co. now owns 1,742,324 shares of the biotechnology company's stock valued at $74,136,000 after acquiring an additional 265,606 shares during the last quarter. GW&K Investment Management LLC lifted its position in shares of Vericel by 12.4% during the 1st quarter. GW&K Investment Management LLC now owns 1,432,434 shares of the biotechnology company's stock valued at $63,915,000 after acquiring an additional 158,470 shares during the last quarter. Geneva Capital Management LLC lifted its position in shares of Vericel by 24.2% during the 1st quarter. Geneva Capital Management LLC now owns 1,365,744 shares of the biotechnology company's stock valued at $60,939,000 after acquiring an additional 265,956 shares during the last quarter. Finally, Wellington Management Group LLP lifted its position in shares of Vericel by 5.8% during the 1st quarter. Wellington Management Group LLP now owns 1,363,644 shares of the biotechnology company's stock valued at $60,846,000 after acquiring an additional 74,723 shares during the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.